GlassScriptPhysician profile
Syed A Shah
NPI 1508867300
$7,312.27
in general payments reported to CMS, 2019-2025
49 companies · $1,214 in 2025
The $1,214 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $58.04 · 2020: $683 · 2021: $1,150 · 2022: $1,398 · 2023: $1,599 · 2024: $1,210 · 2025: $1,214.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,989 · Education: $34.12.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,988.52 |
| Education | $34.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $1,763.50 | 2022-2025 | |
| Abbvie INC. | $558.48 | 2021-2025 | Vraylar |
| Neurocrine Biosciences, INC. | $487.29 | 2021-2025 | Ingrezza, Ongentys |
| Pfizer INC. | $341.78 | 2019-2025 | |
| Eisai INC. | $340.66 | 2020-2025 | |
| Sk Life Science, INC. | $322.70 | 2020-2025 | |
| Sumitomo Pharma America, INC. | $300.30 | 2023-2024 | Aptiom |
| Adamas Pharmaceuticals, INC. | $292.08 | 2020-2021 | |
| Celgene Corporation | $263.83 | 2023-2025 | Zeposia |
| Supernus Pharmaceuticals, INC. | $260.85 | 2019-2024 | Qelbree |
| Argenx US, INC. | $229.90 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Sunovion Pharmaceuticals INC. | $212.18 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $202.23 | 2020-2025 | |
| Allergan, INC. | $200.80 | 2020-2021 | |
| Lilly USA, LLC | $135.43 | 2020-2022 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Syed Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.